The Role of Tuberculosis in Chronic Obstructive Lung Disease
Launched by ISTANBUL MEDENIYET UNIVERSITY · May 1, 2016
Trial Information
Current as of June 18, 2025
Completed
Keywords
ClinConnect Summary
Patients hospitalized with COPD exacerbation were consecutively included (n=598). Cases were classified into two categories: those with a history of TB and those without. Clinical, demographic, and radiological features were meticulously recorded and patients were followed up for mortality. 93 patients (15%) had past TB. On average, patients with a history of TB were four-year younger (p=0.002). Our study revealed that patients with TB history were diagnosed with COPD five-year earlier and died five-year earlier as compared to the patients without TB. In addition, in the TB history positive...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Being diagnosed with COPD exacerbations
- Exclusion Criteria:
- • Not diagnosed with COPD exacerbations
About Istanbul Medeniyet University
Istanbul Medeniyet University is a prominent academic institution based in Turkey, dedicated to advancing medical research and education. As a clinical trial sponsor, the university leverages its extensive resources and expertise to conduct innovative studies aimed at improving healthcare outcomes. With a strong emphasis on ethical standards and scientific rigor, Istanbul Medeniyet University collaborates with healthcare professionals and researchers to explore new therapeutic strategies and contribute to the global body of medical knowledge. Their commitment to fostering a research-driven environment facilitates the development of cutting-edge treatments and enhances patient care within the community and beyond.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Trial Officials
Halil I Yakar, Md
Principal Investigator
Halil Ibrahim Yakar
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials